CLINICAL TRIALS PROFILE FOR THALITONE
✉ Email this page to a colleague
All Clinical Trials for THALITONE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00591773 ↗ | Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension | Completed | Takeda | Phase 3 | 2007-09-01 | The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with chlorthalidone in treating individuals with essential hypertension, compared to treatment with chlorthalidone alone. |
| NCT01203852 ↗ | Pharmacogenomic Evaluation of Antihypertensive Responses 2 | Completed | National Institute of General Medical Sciences (NIGMS) | Phase 4 | 2010-08-01 | There are many medications available for the treatment of high blood pressure (hypertension), but finding the right one for a specific patient can be challenging. In fact, it is estimated that less than 50% of people with hypertension have their blood pressure under control. The hypothesis is that genetic differences between individuals influence their response to antihypertensive medications. This study is aimed at determining the genetic factors that may influence a person's response to either a beta-blocker or a thiazide diuretic. The hope is that through this research, the investigators may someday be able to use an individual's genetic information to guide the selection of their blood pressure medicine, leading to better control of blood pressure, and less need for the current trial and error process. |
| NCT01203852 ↗ | Pharmacogenomic Evaluation of Antihypertensive Responses 2 | Completed | University of Florida | Phase 4 | 2010-08-01 | There are many medications available for the treatment of high blood pressure (hypertension), but finding the right one for a specific patient can be challenging. In fact, it is estimated that less than 50% of people with hypertension have their blood pressure under control. The hypothesis is that genetic differences between individuals influence their response to antihypertensive medications. This study is aimed at determining the genetic factors that may influence a person's response to either a beta-blocker or a thiazide diuretic. The hope is that through this research, the investigators may someday be able to use an individual's genetic information to guide the selection of their blood pressure medicine, leading to better control of blood pressure, and less need for the current trial and error process. |
| NCT02030314 ↗ | The Management of Resistant Hypertension in Kidney Transplant Patients Using Chlorthalidone | Withdrawn | Virginia Commonwealth University | Phase 4 | 2013-07-01 | Chlorthalidone might offer an effective, safe and inexpensive anti-hypertensive treatment for kidney transplant patients who have resistant hypertension on multi-drug therapy. We will collect initial data on the safety and efficacy of Chlorthalidone in the treatment of patients with resistant hypertension. To Examine the efficacy of chlorthalidone as an anti-hypertensive agent in the treatment of resistant hypertension among stable kidney transplant recipients |
| NCT02121041 ↗ | Ambulatory vs Office BP Management Usual Care for Diagnosing and Managing Hypertension: A Pilot Study | Completed | North Carolina Translational and Clinical Sciences Institute | N/A | 2014-05-01 | The purpose of this study is to compare the effectiveness of ambulatory blood pressure monitoring to usual care (blood pressure measurement in the office) in diagnosing and managing hypertension. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for THALITONE
Condition Name
Clinical Trial Locations for THALITONE
Trials by Country
Clinical Trial Progress for THALITONE
Clinical Trial Phase
Clinical Trial Sponsors for THALITONE
Sponsor Name
